search

Active clinical trials for "DiGeorge Syndrome"

Results 31-40 of 47

Put a Face to a Name (Part A): The Effects of Photographic Aids on Patient Satisfaction, Clinician...

Effects of Photographic Aids (Photos of Faces) on Patient Recall of Their Clinical Care TeamEffects of Photographic Aids (Photos of Faces) on Clinician-patient Communication1 more

Communication is critical within healthcare, and is the root cause of most errors. With increased adoption and use of new information technologies and mediated communication systems, such as Electronic Health Records (EHR), that support visual content, hospitals can begin to look at the potential of photographic aids to improve patient satisfaction, clinician communication, and ultimately quality of care. Having pictures of clinicians and patients may improve communication by improving knowledge of who is part of the care team and may reduce electronic ordering or documentation on the wrong patient. Despite the importance of communication between clinicians and the many advances within information and communication technologies, there is a lack of literature documenting systems that are effective at improving communication. Our research study will provide an overview on the communication models and technologies used in Canadian hospitals and add insights to the impacts of these technological adoption. Research Question: How does the use of photographic influence patients' hospital experience? Specifically, do photographic aids (photographs of clinicians' faces) influence: Patient's ability to identify their clinical care team members Patient's ability to identify their care team members and know their individual roles Patient's satisfaction with their hospital experience

Completed3 enrollment criteria

Molecular Variants Associated With Schizophrenia: Differential Analysis of Monozygotic Twins With...

Di George Syndrome

The 22q11.2 microdeletion syndrome (22q11.2DS) is a rare disease with a psychiatric phenotype. Indeed, the diagnosis of schizophrenia is made in 5 to 10% of adolescents and 25 to 40% of adults carrying the 22q11DS. Thus, although this pathology has been able to provide a genetically homogeneous model for the study psychosis etiology, it is not currently possible to establish a link between genomic rearrangement and psychotic symptoms. However, this robust model of genetic vulnerability could provide us a lot of translational informations about schizophrenia genetics. To go furthermore, twin studies have provided us precious data for the study of hereditary diseases. Combining this two approaches, the translational 22q11.2 project proposes a molecular study of two monozygotic 22q11.2DS twins discordant for the psychiatric phenotype -one carrying schizophrenia and the other having no psychiatric symptoms-.

Completed2 enrollment criteria

Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11...

22q11 Deletion Syndrome

The purpose of the present trial is to investigate the effects of omega-3 PUFAs in individuals aged 12-26 years with 22q11DS at ultra-high risk for developing a first episode of psychosis.

Unknown status15 enrollment criteria

Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes...

Williams SyndromeAngelman Syndrome5 more

OBJECTIVES: I. Investigate phenotype and genotype correlations in patients with Smith-Magenis syndrome (SMS) associated with del(17p11.2). II. Clinically evaluate SMS patients with unusual deletions or duplication of proximal 17p. III. Clinically evaluate patients with Williams syndrome with molecular characterization of 7q11.23. IV. Perform clinical studies of Prader-Willi, Angelman, DiGeorge, and Shprintzen syndrome patients with unique molecular findings in 15q11q13 or 22q11.2. V. Perform genotype and phenotype correlations in Prader-Willi patients, particularly those with loss of expression of only some of the imprinted transcripts in 15q11-q13. VI. Evaluate putative Angelman syndrome patients who do not have classic large deletion, uniparental disomy, or imprinting mutations, and perform molecular studies of the Angelman gene, UBE3A, and identify mutations of this gene. VII. Investigate phenotype and genotype correlations in patients with terminal deletions of chromosome 1p.

Completed2 enrollment criteria

Velocardiofacial (VCFS; 22q11.2; DiGeorge) Syndrome Study

DiGeorge SyndromeVelocardiofacial Syndrome1 more

Velocardiofacial syndrome, also known as 22q11.2 syndrome or DiGeorge syndrome, has been associated with many features such as a cleft palate, heart defects, and learning, speech and feeding problems. It is caused by the absence of a number of genes on chromosome 22, but the mechanism by which this inborn abnormality causes the clinical problems is not known. In this study by the National Institute of Mental Health and the Office of Rare Diseases, we are recruiting participants with 22q11.2 syndrome to come for a three-day stay to our main campus in Bethesda, MD, to participate in a study in which we will investigate the genetic makeup of their cells together with several studies of brain function with advanced research imaging. The goal of this study is to understand how the genes missing in 22q11.2 syndrome are related to the increased occurrence of psychiatric problems, such as psychosis, in this syndrome. Participants must be 18-50 years of age, have some high school education and not currently be taking antipsychotic medication. Travel costs to Bethesda for participants and an accompanying person will be paid, and participants are reimbursed for their time in participating in the study. A blood draw is required. All research procedures have been designated as "minimal risk" procedures. ...

Completed2 enrollment criteria

Prevalence and Clinical Spectrum of the 22q11 Deletion

Congenital Disorders

The purpose of this project is to conduct population based surveillance for prenatally diagnosed congenital defects amount residents of the five counties to: improve the comprehensiveness of the Metropolitan Atlanta Congenital Defects Program (MACDP) to (1) better fulfill its objectives (2) allow assessment of the impact of prenatal diagnosis and elective termination on the birth prevalence of congenital defects in Atlanta (3) develop a registry of prenatally diagnosed defects to be used in epidemiologic and genetic studies, in evaluation prevention programs and in monitoring prenatal diagnostic technology.

Terminated3 enrollment criteria

Infection in DiGeorge Following CHD Surgery

DiGeorge SyndromeCongenital Heart Defects

We propose a retrospective review of patients with DiGeorge syndrome having undergone cardiac surgery to evaluate the incidence of blood stream and/or surgical site infection. The hypothesis is that we will find an increased number of infections for this sub-group. We will compare the incidence of infection to children of similar age and diagnosis to evaluate for variances in the incidence of infection.

Terminated2 enrollment criteria

Middle and Inner Ear Malformation in Children With Velocardiofacial Syndrome

Ear Malformations in the Velocardiofacial Syndrome

Middle and inner ear malformations on two boys with velocardiofacial syndrome are discussed.Special attention should be given to the presence of hearing loss due to middle and inner ear malformations, in addition to frequent conductive hearing loss regarding mastoid and middle ear inflammatory processes.

Completed1 enrollment criteria

Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome

Immune Defect22q11.2 Deletion Syndrome

Evaluate about age of resolution in immune defect in 22q11.2 Deletion Syndrome Incidence of immunodeficiencies in 22q11.2 Deletion Syndrome

Completed2 enrollment criteria

SNP-based Microdeletion and Aneuploidy RegisTry (SMART)

22q11 Deletion SyndromeDiGeorge Syndrome9 more

This multi-center prospective observational study is designed to track birth outcomes and perinatal correlates to the Panorama prenatal screening test in the general population among ten thousand women who present clinically and elect Panorama microdeletion and aneuploidy screening as part of their routine care. The primary objective is to evaluate the performance of Single Nucleotide Polymorphism (SNP)-based Non Invasive Prenatal Testing (NIPT) for 22q11.2 microdeletion (DiGeorge syndrome) in this large cohort of pregnant women. This will be done by performing a review of perinatal medical records and obtaining biospecimens after birth to perform genetic diagnostic testing for 22q11.2 deletion. Results from the follow-up specimens will be compared to those obtained by the Panorama screening test to determine test performance. Specific test performance parameters will include: PPV, specificity, and sensitivity.

Completed8 enrollment criteria
1...345

Need Help? Contact our team!


We'll reach out to this number within 24 hrs